ReviewCurrent opinion in organ transplantation2013
Clinical translation of autologous Schwann cell transplantation for the treatment of spinal cord injury.
Review in Current opinion in organ transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 98 citations in OpenAlex.
- Scalable culture techniques to generate large numbers of purified human Schwann cells for clinical trials in human spinal cord and peripheral nerve injuries.Journal of neurosurgery. Spine · 2022Trial
- Trial
- Pathologic and Therapeutic Schwann Cells.Cells · 2025Review
- Engineered Healing: Synergistic Use of Schwann Cells and Biomaterials for Spinal Cord Regeneration.International journal of molecular sciences · 2025Review
- Article
- Schwann Cells and Their Exosomes: Research Progress and Prospect in Spinal Cord Injury.Neural plasticity · 2025Review
- Schwann cells in regeneration and cancer.Frontiers in pharmacology · 2025Review
- Schwann cells acquire a repair phenotype after assembling into spheroids and show enhanced in vivo therapeutic potential for promoting peripheral nerve repair.Bioengineering & translational medicine · 2024Article
- Unleashing Axonal Regeneration Capacities: Neuronal and Non-neuronal Changes After Injuries to Dorsal Root Ganglion Neuron Central and Peripheral Axonal Branches.Molecular neurobiology · 2024Review
- Schwann Cell-Derived Exosomal Vesicles: A Promising Therapy for the Injured Spinal Cord.International journal of molecular sciences · 2023Review
- Transplantation of autologous bone marrow-derived mononuclear cells into cerebrospinal fluid in a canine model of spinal cord injury.Regenerative therapy · 2023Article
- Human Schwann Cells in vitro III. Analytical Methods and a Practical Approach for Quality Control.Bio-protocol · 2023Article
- Human Schwann Cells in vitro I. Nerve Tissue Processing, Pre-degeneration, Isolation, and Culturing of Primary Cells.Bio-protocol · 2023Article
- A Multi-Stage Bioprocess for the Expansion of Rodent Skin-Derived Schwann Cells in Computer-Controlled Bioreactors.International journal of molecular sciences · 2023Article
- Review
- Phase 1 Safety Trial of Autologous Human Schwann Cell Transplantation in Chronic Spinal Cord Injury.Journal of neurotrauma · 2022Article
- Cell transplantation to repair the injured spinal cord.International review of neurobiology · 2022Article
- Repair of the Injured Spinal Cord by Schwann Cell Transplantation.Frontiers in neuroscience · 2022Review
- Heregulin Activity Assays for Residual Testing of Cell Therapy Products.Biological procedures online · 2021Article
- Schwann cell remyelination of the central nervous system: why does it happen and what are the benefits?Open biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo describe the current status of testing Schwann cell transplantation as a therapy for human spinal cord injury (SCI). RECENT
findingsTransplanted Schwann cells have reparative effects in the damaged spinal cord. A few clinical studies have reported that Schwann cell transplantation appears safe. Compared with allogeneic cell transplants, autologous cells do not require immune suppression, but the workload of cell manufacturing is greater. Preclinical Schwann cell transplant studies conducted at the University of Miami in 2009-2012 supported an investigational new drug approved by the Food and Drug Administration. A Phase 1 safety study has been initiated. SUMMARY: Spinal cord repair after severe SCI requires that axonal regeneration and myelination occur in a context of reduced inhibition, enhanced plasticity, and new circuit formation. Evolving clinical experience with Schwann cell transplantation may provide a basis upon which additionally combined therapeutics can be tested to increase the extent of repair after SCI. Safety is the primary consideration when ex-vivo manipulated cells are introduced into the damaged nervous system. Preclinical studies across several species have not indicated safety concerns regarding Schwann cells. Initial clinical reports from studies in Iran and China are suggestive of clinical safety, although more rigorous characterization of the implanted cells is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.